SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.24+5.1%12:12 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (16771)5/13/2005 5:31:34 PM
From: Biomaven  Read Replies (2) of 52153
 
Digging some more, I note that the carboplatin and paclitaxel combo sometimes produces RR's of around 30% by itself in naive advanced NSCLC. So that Tarceva number I quoted earlier was low - might have been a different patient population somehow?

And a cautionary note from a friend - these small early trials often have cherry-picked patients. But still, even if these patients were cherry-picked, these are encouraging early results.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News